Clinical Neurophysiology Department, Gregorio Marañón University Hospital, Madrid, Spain.
Sleep Med. 2011 Jan;12(1):24-7. doi: 10.1016/j.sleep.2010.02.017. Epub 2010 Nov 2.
To report our findings from a sample of narcoleptic children and adolescents evaluated in our unit from 1988 to 2005.
The sample was composed of nine children (5 boys) with a mean age of 14.5 years at diagnosis. The protocol included the following: Epworth, Ullanlinna narcolepsy scale, and Stanford cataplexy questionnaires; physical, psychological and neurological examinations; neuroimaging; PSG+MSLT recordings; HLA and in two cases Hcrt-1 level in CSF.
Narcolepsy was sporadic in all cases. The first symptom was EDS with a mean age at onset of 9.4±2.5 years (range 6-13 years). All patients complained of cataplexy. Other symptoms were hypnagogic hallucinations (4 children) and sleep paralysis (3 children). All the children performed poorly at school, 4 had emotional disorders with depression, 4 displayed nocturnal eating and weight gain. Mean BMI was 25.0 kg/m(2). One girl was diagnosed as having precocious puberty, polycystic ovary syndrome (PCOS), hyperandrogenism and insulin resistance. The MRI showed a partial empty sella. Hcrt-1 was undetectable in her CSF. The mean Ullanlinna score was 24.6; PSG showed disturbed nocturnal sleep and the MSLT showed a mean sleep latency of 2.1 min and 3 SOREMPs. Eight children were DR2-DQ1-positive, whereas one boy was DR2-negative but DQ1-positive. In two patients, Hcrt-1 was undetectable. All children, in addition to scheduled naps during the day, were treated with modafinil or methylphenidate combined with an antidepressant and in two cases with sodium oxybate.
NC was sporadic in all children and associated with precocious puberty and PCOS, hyperandrogenism and insulin resistance in one case. EDS, cataplexy, disturbed nocturnal sleep, nocturnal eating, poor school performance, and emotional disorders were the principal complaints. All patients had DQB1∗0602 and Hcrt-1 was evaluated in two cases (undetectable in both).
报告我们从 1988 年至 2005 年在本单位评估的一组发作性睡病儿童和青少年患者中得出的发现。
该样本由 9 名儿童(5 名男孩)组成,诊断时的平均年龄为 14.5 岁。该方案包括以下内容:Epworth、Ullanlinna 发作性睡病量表和斯坦福猝倒问卷;体格检查、心理和神经检查;神经影像学;PSG+MSLT 记录;HLA 和 2 例患者脑脊液中的 Hcrt-1 水平。
所有病例均为散发性发作性睡病。首发症状为 EDS,发病年龄平均为 9.4±2.5 岁(6-13 岁)。所有患者均主诉猝倒。其他症状包括催眠幻觉(4 例)和睡眠瘫痪(3 例)。所有患儿学习成绩均较差,4 例存在情绪障碍伴抑郁,4 例存在夜间进食和体重增加。平均 BMI 为 25.0kg/m²。1 例女孩被诊断为性早熟、多囊卵巢综合征(PCOS)、高雄激素血症和胰岛素抵抗。MRI 显示部分空蝶鞍。其脑脊液中 Hcrt-1 无法检出。Ullanlinna 评分平均为 24.6;PSG 显示夜间睡眠紊乱,MSLT 显示平均睡眠潜伏期为 2.1 分钟和 3 次 SOREMP。8 例患儿为 DR2-DQ1 阳性,1 例男孩为 DR2 阴性但 DQ1 阳性。2 例患者 Hcrt-1 无法检出。除白天安排小睡外,所有患儿均接受莫达非尼或哌甲酯治疗,联合使用抗抑郁药,2 例患者还使用了羟丁酸钠。
所有患儿均为散发性发作性睡病,1 例患儿伴有性早熟和 PCOS、高雄激素血症和胰岛素抵抗。EDS、猝倒、夜间睡眠紊乱、夜间进食、学习成绩较差和情绪障碍是主要主诉。所有患者均携带 DQB1∗0602,2 例患者(均未检出)检测了 Hcrt-1。